



SUPPLEMENTARY MATERIALS


Supplementary Figure 1. C-144-01 Study Design



Four cohorts were enrolled in the C-144-01 trial as shown in the study design. The total planned sample size was approximately 171 patients. The present report focused on the efficacy and safety of lifileucel in patients enrolled in Cohorts 2 and 4.

Abbreviations: ICI, immune checkpoint inhibitors; TIL, tumor-infiltrating lymphocytes.


Supplementary Figure 2. CONSORT Diagram for Pooled Cohorts 2 and 4

Supplementary Figure 3. Sankey Plot of Treatment Patterns

The Sankey plot shows the treatment journey of the patients with various regimen types used. The R package networkD3 was used to generate the Sankey plot.

1L–10L represent lines of therapy.


Abbreviations: ICI, immune checkpoint inhibitors; L, line of therapy.

Supplementary Figure 4. Overall Survival, by Response Status at 1.5 Months After Lifileucel Infusion

Abbreviations: OS, overall survival; NR, not reached

Survivors at 1.5 months (~6 weeks, first response assessment after lifileucel infusion) were stratified by response status, and overall survival from the 1.5-month landmark was computed using Kaplan Meier methods.

Supplementary Figure 5. Site of Tumor Resection and Infused Cell Dose



Abbreviations: BOR, best overall response; CR, complete response; IRC, Independent Review

Committee; PD, progressive disease; PR, partial response; SD, stable disease; SOD, sum of diameters.

Supplementary Table 1. Tumor-resection AEs* Related to Surgery Occurring in >1 Patient (Any Grade) in the Tumor Harvested Set (N=189)

Preferred Term, n (%)	Tumor Harvested Set (N=189)	
	Any Grade	Grade 3/4
Number of patients reporting >1 tumor-resection AE related to surgery	60 (31.7)	6 (3.2)
Procedural pain	22 (11.6)	0
Nausea	5 (2.6)	1 (0.5)
Vomiting	4 (2.1)	0
Abdominal pain	3 (1.6)	1 (0.5)
Cellulitis	3 (1.6)	2 (1.1)
Flank pain	3 (1.6)	0
Incision site erythema	3 (1.6)	0
Seroma	3 (1.6)	0
Decreased appetite	2 (1.1)	0
Erythema	2 (1.1)	0
Incision site pain	2 (1.1)	0
Localized edema	2 (1.1)	0
Lymphocele	2 (1.1)	0
Postoperative wound infection	2 (1.1)	0
Wound dehiscence	2 (1.1)	0

Abbreviations: AE, adverse event; NMA-LD, nonmyeloablative lymphodepletion.

*Tumor-resection AEs refer to AEs that started after tumor resection and before the start of NMA-LD.

For patients who did not receive NMA-LD, AEs up to 30 days from tumor resection were included.